



SHIELD

Innovative multiplex immunoassays and AI for comprehensive early detection and monitoring of high-risk individuals with pancreatic cancer



Our mission

SHIELD is developing a simple blood test for early detection of pancreatic cancer.

By focusing on people with elevated genetic risk, it aims to reduce late-stage diagnoses and increase Europe's five-year survival rate to 30% by 2035.



Detection

Early detection for high-risk individuals enables timely diagnosis.



Diagnostics


A cost-effective blood test for fast, affordable, and accurate diagnosis.



Impact

Fewer late diagnoses lead to earlier treatments and reduce overall mortality.

Discover more
about SHIELD



The Consortium



Learn more about SHIELD:



missionshield.eu



mastodon.social/@MissionSHIELD



info@missionshield.eu



[@SHIELD project](https://www.linkedin.com/company/shield-project/)



Co-funded by
the European Union



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Federal Department of Economic Affairs
Education and Research ERAR
Stato Secretariat for Education,
Research and Innovation SERI